Subsequent Events |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Subsequent Events [Abstract] | |
| Subsequent Events | 10. Subsequent Events
On July 16, 2026, the Board approved the acceleration of vesting of all outstanding unvested options and RSAs held by the Company's officers and directors.
On July 16, 2026, the Company noted the holder of 351,037 shares of non-voting Series A Convertible Preferred Stock converted all of his 351,037 shares of the Company’s Series A Convertible Preferred Stock into an equal number of shares of common stock.
On July 16, 2026, 110,984 vested options held by a director of the Company with an exercise price per share range between $24.20 and $369.40 were cancelled.
On July 24, 2026, the Securities and Exchange Commission (SEC) approved the effectiveness of the Form S-4 filing pursuant to the Merger Agreement with Korsana Biosciences, Inc. |